Targeting KRAS in pancreatic cancer: new drugs on the horizon

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Kirsten Rat Sarcoma (KRAS) is a key oncogene regulating cell growth and survival.
• Activating KRAS mutations are prevalent in over 90% of pancreatic ductal adenocarcinoma (PDAC) and drive tumor development.
• KRAS has historically been a difficult therapeutic target due to its challenging molecular structure.

Purpose of the Study:

• To review the role of KRAS signaling in pancreatic cancer.
• To discuss historical and recent therapeutic strategies targeting KRAS mutations.
• To explore challenges, successes, and resistance mechanisms in KRAS-targeted therapy.

Main Methods:

• Literature review of KRAS signaling pathways.
• Analysis of drug discovery efforts targeting KRAS.
• Examination of clinical data on KRAS inhibitors and resistance.

Main Results:

• KRAS mutations are critical drivers in PDAC.
• Previous indirect targeting strategies for KRAS were largely unsuccessful.
• Novel inhibitors targeting specific KRAS mutations, like KRAS G12C, have emerged as promising therapeutic options.

Conclusions:

• Targeting KRAS, once considered undruggable, is now a reality for specific mutations.
• Understanding resistance mechanisms is crucial for durable responses in KRAS-mutated cancers.
• Future research should focus on overcoming resistance and expanding targeted therapies for KRAS-driven malignancies.